Stock Track | Amneal Pharmaceuticals Surges as Barclays Reaffirms Buy Rating

Stock Track11-11

Shares of Amneal Pharmaceuticals, Inc. (AMRX) soared 5.04% on November 11th, after Barclays analyst Balaji Prasad reiterated a Buy rating on the stock and set a price target of $10.00.

Prasad's positive rating and price target suggest that Barclays believes Amneal Pharmaceuticals' stock is currently undervalued and has further upside potential. The analyst's optimism about the company's prospects has boosted investor confidence, leading to increased buying interest and driving the stock's price higher.

Amneal Pharmaceuticals is a specialty pharmaceutical company that develops, manufactures, and markets generic and branded pharmaceutical products. The company's diverse product portfolio and pipeline have positioned it well for continued growth in the rapidly evolving healthcare industry.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1100954143?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-11 23:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1100954143","market":"us","top_or_hot":-1,"title":"Stock Track | Amneal Pharmaceuticals Surges as Barclays Reaffirms Buy Rating","media":"Stock Track","content":"<p>Shares of Amneal Pharmaceuticals, Inc. (AMRX) soared 5.04% on November 11th, after Barclays analyst Balaji Prasad reiterated a Buy rating on the stock and set a price target of $10.00.</p>\n\n<p>Prasad's positive rating and price target suggest that Barclays believes Amneal Pharmaceuticals' stock is currently undervalued and has further upside potential. The analyst's optimism about the company's prospects has boosted investor confidence, leading to increased buying interest and driving the stock's price higher.</p>\n\n<p>Amneal Pharmaceuticals is a specialty pharmaceutical company that develops, manufactures, and markets generic and branded pharmaceutical products. The company's diverse product portfolio and pipeline have positioned it well for continued growth in the rapidly evolving healthcare industry.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Amneal Pharmaceuticals Surges as Barclays Reaffirms Buy Rating</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Amneal Pharmaceuticals Surges as Barclays Reaffirms Buy Rating\n</h2>\n\n<h4 class=\"meta\">\n\n2024-11-11 23:16 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Amneal Pharmaceuticals, Inc. (AMRX) soared 5.04% on November 11th, after Barclays analyst Balaji Prasad reiterated a Buy rating on the stock and set a price target of $10.00.\nPrasad's ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AMRX","symbol_name":"Amneal Pharmaceuticals, Inc.","start_time":0,"source_url":"","article_id":"1100954143","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1100954143","pubTimestamp":1731338188,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Amneal Pharmaceuticals, Inc.  soared 5.04% on November 11th, after Barclays analyst Balaji Prasad reiterated a Buy rating on the stock and set a price target of $10.00.Prasad's positive rating and price target suggest that Barclays believes Amneal Pharmaceuticals' stock is currently undervalued and has further upside potential. The analyst's optimism about the company's prospects has boosted investor confidence, leading to increased buying interest and driving the stock's price higher.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AMRX":"Amneal Pharmaceuticals, Inc."},"translate_title":"巴克莱重申买入评级，Amneal Pharmaceuticals股价飙升","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AMRX":1},"content_text":"Shares of Amneal Pharmaceuticals, Inc. (AMRX) soared 5.04% on November 11th, after Barclays analyst Balaji Prasad reiterated a Buy rating on the stock and set a price target of $10.00.\nPrasad's positive rating and price target suggest that Barclays believes Amneal Pharmaceuticals' stock is currently undervalued and has further upside potential. The analyst's optimism about the company's prospects has boosted investor confidence, leading to increased buying interest and driving the stock's price higher.\nAmneal Pharmaceuticals is a specialty pharmaceutical company that develops, manufactures, and markets generic and branded pharmaceutical products. The company's diverse product portfolio and pipeline have positioned it well for continued growth in the rapidly evolving healthcare industry.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1100954143"}